



Research article

Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice

Vladimir N. Anisimov^{1,*}, Vladimir Kh. Khavinson², Irina G. Popovich¹, Mark A. Zabezhinski¹, Irina N. Alimova¹, Svetlana V. Rosenfeld³, Natalia Yu. Zavarzina¹, Anna V. Semenchenko⁴ & Anatoli I. Yashin⁴

¹Department of Carcinogenesis and Oncogerontology, N.N. Petrov Research Institute of Oncology, Pesochny-2, St. Petersburg, 197758, Russia; ²St. Petersburg Institute of Bioregulation and Gerontology, 3, pr. Dynamo, 197110, Russia; ³I.P. Pavlov State Medical University, Lev Tolstoy Str., 6/8, St. Petersburg, 197022, Russia; ⁴Max-Planck Institute for Demographic Research, Doberaner Str., 114, Rostock 18057, Germany; *Author for correspondence (e-mail: aging@mail.ru; fax: +7-812-596-8947)

Received 7 November 2002; accepted in revised form 2 January 2003

Key words: chromosome aberrations, Epitalon, estrous cycle, life span, SHR mice, spontaneous tumors

Abstract

From the age of 3 months until their natural deaths, female outbred Swiss-derived SHR mice were subcutaneously injected on 5 consecutive days every month with 0.1 ml of normal saline (control) or with 1.0 $\mu\text{g}/\text{mouse}$ ($\sim 30\text{--}40 \mu\text{g}/\text{kg}$) of tetrapeptide Epitalon[®] (Ala-Glu-Asp-Gly) dissolved in 0.1 ml saline. There were 54 mice in each group. The results of this study show that treatment with Epitalon did not influence food consumption, body weight or mean life span of mice. However, it slowed down the age-related switching-off of estrous function and decreased the frequency of chromosome aberrations in bone marrow cells (by 17.1%, $P < 0.05$). It also increased by 13.3% the life span of the last 10% of the survivors ($P < 0.01$) and by 12.3% the maximum life span in comparison with the control group. We also found that treatment with Epitalon did not influence total spontaneous tumor incidence, but inhibited the development of leukemia (6.0-fold), as compared with the control group. The data obtained suggest a geroprotector activity of Epitalon and the safety of its long-term administration in mice.

Introduction

The search for new effective and safe means to prevent premature aging is one of the priorities in gerontology (Anisimov 2001; Butler et al. 2002; De Grey et al. 2002). During the last decade a number of reports have appeared on the role of the pineal gland in aging (Armstrong and Redman 1991; Reiter 1995; Reppert and Weaver 1995; Pierpaoli 1998; Reiter et al. 2002). A modulating effect of the pineal gland on the neuroendocrine and the immune system was shown to change during aging (Arendt 1995). Pinealectomized rats showed a reduced life span (Malm et al. 1956; Reiter et al. 1999), whereas the adminis-

tration of the pineal hormone melatonin to rodents or syngeneic transplantation of pineal glands from young donors into the thymus or *in situ* of old mice prolonged the life span of the recipients (Pierpaoli and Regelson 1994; Lesnikov and Pierpaoli 1994; Anisimov et al. 2001b; Oxenkrug et al. 2001). Most investigators invoked melatonin as a primary mediator of the endocrine capabilities of the pineal gland. However, some of the effects of the pineal gland might have obviously resulted from pineal peptide secretion (Benson 1977; Bartsch et al. 1992; Yuwiler and Brammer 1993; Arendt 1995). Some crude peptide extracts or purified peptides isolated from pineal glands were shown to have antigonadotropic, metabolic and anti-

tumor activity (Anisimov et al. 1994; Bartsch et al. 1992; Lapin and Ebels 1979). One of the complex peptide bioregulators isolated from the pineal gland, Epithalamin[®], was shown to slow down aging rate, prolong life span in fruit flies, mice and rats, and inhibit spontaneous and induced carcinogenesis in rodents (Anisimov et al. 1994; Khavinson et al. 2001c; Khavinson 2002).

Tetrapeptide Epitalon[®] (Ala-Glu-Asp-Gly, molecular weight 390.35 dalton) was designed on the basis of Epithalamin amino acid analysis and synthesized (Khavinson et al. 2000). The geroprotective activity of Epitalon was studied in three strains of *Drosophila melanogaster* (Khavinson et al. 2000; Mylnikov and Lyubimova 2000). Epitalon increased the life span of imagoes significantly by 11–16% when applied at unprecedentedly low concentrations – from 0.001×10^{-6} to 5×10^{-6} wt% of the culture medium. A recent study by us demonstrated a geroprotective effect of long-term Epitalon administration in female inbred CBA mice (Anisimov et al. 2001a). The bioregulator slowed down aging of the reproductive function, inhibited free radical processes, and decreased total spontaneous tumor incidence in female CBA mice (Anisimov et al. 2001a). Epitalon inhibited mammary carcinogenesis and metastasis in transgenic *HER-2/neu* mice (Anisimov et al. 2002b) and colon and small intestine carcinogenesis induced by 1,2-dimethylhydrazine in rats (Anisimov et al. 2002a). Administration of Epitalon to young (6–8 years old) and senescent (20–26 years old) female monkeys *Macaca mulatta* restored the evening level of melatonin and the circadian rhythm of cortisol in the blood serum of senescent monkeys (Khavinson et al. 2001a).

This paper presents data on the effect of Epitalon on life span, estrous function, incidence of chromosome aberration in the bone marrow cells and spontaneous tumorigenesis in outbred Swiss-derived SHR mice.

Materials and methods

Animals

Female outbred Swiss-derived SHR 2-month-old mice (108 specimens) were purchased from the Rappolovo Animal Farm of the Russian Academy of Medical Sciences (St. Petersburg). The mice were kept in polypropylene cages (30 × 21 × 9 cm), 5 mice to a

cage, at a temperature of $22 \pm 2^\circ\text{C}$. A regimen was followed of 12 hours of light and 12 hours of dark. The animals received sterilized standard laboratory feed (Anisimov et al. 2003) and tap water *ad libitum*. Mice were checked daily by animal care personnel and weekly by a veterinarian. The study was conducted in accordance with the regulations for ensuring the humane treatment of animals under the approval of the Committee on Animal Research of the N.N. Petrov Research Institute of Oncology.

Experiment

At the age of 3 months the mice were randomly divided into two groups, 54 animals in each, and they were individually marked. Mice of the control group were subcutaneously injected with 0.1 ml of 0.9% normal saline for 5 consecutive days every month, whereas the mice of the second group received subcutaneously 1.0 μg of Epitalon dissolved in 0.1 ml of saline. This treatment dosage and regimen were effective for the inhibition of spontaneous tumorigenesis in female CBA mice (Anisimov et al. 2001a). Epitalon was synthesised in St. Petersburg, Institute of Bioregulation and Gerontology, by E.I. Grigoriev and was 99.8% pure. Four intact female SHR mice were euthanized at the age of three months to evaluate the initial level of chromosome aberrations. Additionally four mice from each group were euthanized at the age of 12 months for a cytogenetic study of chromosome aberrations in bone marrow cells (see below). Once every 3 months, simultaneously with weighing, the amount of food consumed was measured. Thirty grams of food were given in each cage after cleaning and twenty-four hours thereafter the food that had not been consumed was collected from each cage and weighed. The mean amount of food (grams) consumed per mouse during this day was calculated for each group.

Once every three months, vaginal smears taken daily for two weeks from the animals were examined cytologically to estimate the phases of their estrous functions. In the same period, the rectal body temperatures of the mice were measured with an electronic thermometer, TPEM (KMIZ, Russia). Animals were observed until their natural death. The date of each death was recorded, and the mean life span, the age by which 90% of the animals died, and the maximum life span were estimated.

Cytogenetic study

Chromosomal aberrations in bone marrow cells were studied by a modified Ford's method, described by Rosenfeld et al. (2001). Mice were sacrificed by ether anaesthesia. Both femurs of each mouse were dissected and bone marrow cells were flushed gently with 0.56% KCl solution into a centrifuge tube. Cells were treated for 20 min with hypotonic solution and fixed with an ethanol : acetic acid mixture (3:1). Slides were stained with 4% aceto-orseine: 20–30 well spread anaphases were analyzed for each animal and cells with chromosome breaks, acentric fragments, and other aberrations were evaluated at 1000× magnification under a light microscope (Leitz, Germany).

Pathomorphological examination

All animals that died, or were sacrificed when moribund, were autopsied and their skin and internal organs were examined. Neoplasias were classified according to the recommendations of the International Agency of Research on Cancer (IARC) as 'fatal' (i.e., those that directly caused the death of the animal) or 'incidental' (in cases where the animal died of a different cause) (Gart et al. 1986). All tumors, as well as tissues and organs with suspected tumors, were excised and fixed in 10% neutral formalin. After routine histological processing, tissues were embedded in paraffin. Thin, 5–7 μm histological sections were stained with hematoxylin-eosine and examined microscopically. The experimental group to which the mouse belonged was blinded. Tumors were classified according to IARC recommendations (Turusov and Mohr 1994).

Statistics

Experimental results were statistically processed by the methods of variation statistics (Goubler 1978). The significance of discrepancies was defined according to Student's *t*-criterion, Fischer's exact method, χ^2 -analysis, and the non-parametric criterion of Wilcoxon–Mann–Whitney (Goubler 1978). To estimate discrepancies in neoplasm incidence, an IARC method of combined contingency tables calculated individually for the fatal and incidental tumors (Gart et al. 1986). For survival analysis, Cox's method (Cox and Oakes 1996) was used. All reported test values for survival analyses are two-sided.

Survival models and estimations

The mathematical model used to describe survival is the Gompertz model with the survival function:

$$S(x) = \exp \left\{ -\frac{\beta}{\alpha} [\exp(\alpha x) - 1] \right\}$$

where parameters α and β are associated with demographic aging and initial mortality rate, respectively. Parameters for the model were estimated from data using the maximum likelihood method implemented in the GAUSS statistical system (Gauss System 1994). Confidence intervals for the aging rate parameter estimates were calculated using log-likelihood functions (Cox and Oakes 1994).

Results

Age-related body weight dynamics

Mean values of body weight for mice at different ages in the control and treated with Epitalon groups are displayed in Table 1. The body weight of the mice in both groups increased with age, exceeding by 13 months the body weight of 3-month-old animals by 44.5% in the control group ($P < 0.001$), and by 48.5% in the group given Epitalon ($P < 0.01$). There were no differences in the body weight between groups at any period of observation.

Age-related dynamics of food consumption

Measurements showed that the amount of food consumed by the mice in the control (saline) group was practically stable from the age of 5 months to the age of 16 months, increasing slightly at the age of 18 months. Mice treated with Epitalon consumed more food from the 5th to the 16th months of their life than the control group (Table 2).

Age-related dynamics of estrous function in mice

The estrous function in the animals of both age groups was examined every three months, starting when the mice were three months old. The following parameters of estrous function were estimated: the length of the estrus, the relative rate of estrous cycle phases (in percent); and the relative number of short (< 5 days) and long (> 5 days) estrous cycles. The relative number of animals with regular cycles and irregular

Table 1. Body weight gain dynamics in female SHR mice treated with saline or Epitalon

| Group | Body weight (g) | | | | | | | |
|----------|-----------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| | 3 mo | 5 mo | 7 mo | 9 mo | 11 mo | 13 mo | 16 mo | 18 mo |
| Saline | 24.7 ± 0.29 | 27.8 ± 0.63 | 30.9 ± 0.85 | 32.4 ± 1.30 | 34.3 ± 1.24 | 35.7 ± 1.67 | 34.0 ± 1.73 | 32.4 ± 1.50 |
| Epitalon | 24.1 ± 0.41 | 28.1 ± 0.40 | 30.1 ± 0.74 | 33.2 ± 1.04 | 34.4 ± 1.08 | 35.8 ± 1.68 | 33.9 ± 1.67 | 30.7 ± 1.49 |

Table 2. Food consumption dynamics in female SHR mice treated with saline or Epitalin

| Group | Daily food consumption (g/mouse) | | | | | | | |
|----------|----------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|------------|
| | 3 mo | 5 mo | 7 mo | 9 mo | 11 mo | 13 mo | 16 mo | 18 mo |
| Saline | 4.6 ± 0.03 | 2.8 ± 0.05 | 3.3 ± 0.02 | 2.8 ± 0.03 | 3.1 ± 0.01 | 3.4 ± 0.03 | 3.8 ± 0.06 | 5.3 ± 0.15 |
| Epitalon | 4.3 ± 0.17 | 4.9 ± 0.15* | 5.4 ± 0.09* | 5.6 ± 0.13* | 5.6 ± 0.22* | 5.7 ± 0.24* | 5.9 ± 0.32* | 5.8 ± 0.47 |

The difference from the saline group is significant. * - $P < 0.001$ (Student's t -test).

cycles (persistent estrus and anestrus) were also calculated. Judging by the data presented in Table 3, the length of estrous cycle in the control female SHR mice increased with advancing age ($P < 0.05$; Student's t -test). Thus, no essential age-related alterations in the rate of estrous cycle phases were observed. However, the relative number of short estrous cycles decreased significantly with age (37.1% at the age of 3 months, 9.4% at the age of 12 months ($P < 0.05$; Fischer's exact test) and zero at the age of 15 months, whereas the number of long cycles rose (5.1% at the age of 6 months and 36% at the age of 15 months, $P < 0.05$; Fischer's exact test).

In the group of mice exposed to Epitalon the length of estrous cycles did not change with the age of the animals and decreased in comparison with the age-matched controls at the age of 15 months ($P < 0.05$). There was no significant age-related decrease in the number of short cycles, or an increase in the number of long cycles. The number of mice with regular cycles did not change significantly with age in both groups (Table 3).

Age-related dynamics of body temperature in mice

Data on body temperature alterations in the mice exposed to saline or Epitalon are presented in Table 4. The control mice and mice treated with Epitalon revealed a significant decrease in body temperature with age, both on the whole (irrespective of the estrous cycle phases) and in any of the phases. No cyclic alterations in rectal body temperature during the estrous cycle were observed in mice of the control group, but

the temperature at diestrus was significantly higher than that in estrus in mice treated with Epitalon at the age of 15 months ($P < 0.05$). It should be noted that the average body temperature in the mice treated with Epitalon was not significantly different from the control mice during the entire period of observation (Table 4).

Chromosome aberrations in mouse bone marrow cells

The incidence of chromosome aberrations in bone marrow cells of 3-month-old female SHR was $2.1 \pm 0.29\%$. At the age of 12 months this parameter increased to $8.2 \pm 0.41\%$ ($P < 0.001$; Wilcoxon-Mann-Whitney test) in the group injected with saline. In mice treated from the age of 3 months with Epitalon the incidence of chromosome aberrations at the age of 12 months was 6.8 ± 0.21 (-17.1%; $P < 0.05$).

Survival and longevity of female SHR mice

Survival dynamics in the mice treated with either saline or DSIP are demonstrated in Table 5 and Figure 1. The survival dynamics were in general similar in all groups up to the age of 22 months. However, thereafter, the number of survivors was much higher in Epitalon-treated groups.

The last mouse in the control group died at the age of 739 days (24.3 months), whereas in the groups treated with Epitalon 12% of mice survived to this age, and the maximum life span was 830 days (27.3 months, +12.3%). The mean life span of mice treated with Epitalon did not change as compared with controls. However, the life span in the last 10% of the

Table 3. Age-related dynamics of estrous functional parameters in SHR mice treated with saline or Epitalon

| Age (mo) | No. of mice | Length of estrous cycle (days) | Rate of separate phases of estrous cycle (%) | | | Rate of estrous cycles (%) | | | Rate of mice with regular cycles (%) | Rate of mice with irregular cycles (%) |
|----------|-------------|--------------------------------|--|------|-------|----------------------------|-------|--------|--------------------------------------|--|
| | | | E | D | P + M | < 5 d | 5–7 d | > 7 d | | |
| Saline | | | | | | | | | | |
| 3 | 28 | 5.68 ± 0.19 | 42.4 | 54.7 | 2.9 | 31.7 | 55.0 | 13.3 | 88.0 | 12.0 |
| 6 | 22 | 5.38 ± 0.19 | 45.4 | 50.5 | 4.1 | 30.8 | 64.1 | 5.1 | 95.5 | 4.5 |
| 9 | 22 | 5.77 ± 0.30 | 34.2 | 62.4 | 3.4 | 25.6 | 59.0 | 15.4 | 95.5 | 4.5 |
| 12 | 22 | 6.25 ± 0.26 | 47.1 | 51.3 | 1.6 | 9.4** | 81.2 | 9.4 | 95.5 | 4.5 |
| 15 | 17 | 6.84 ± 0.26* | 34.2 | 65.1 | 0.7 | 0** | 64.0 | 36.0** | 88.2 | 11.8 |
| Epitalon | | | | | | | | | | |
| 3 | 50 | 5.87 ± 0.24 | 42.8 | 53.1 | 4.1 | 29.1 | 47.3 | 23.6 | 100 | 0 |
| 6 | 48 | 5.81 ± 0.23 | 46.5 | 48.9 | 4.6 | 16.2 | 75.7 | 8.1 | 91.4 | 8.6 |
| 9 | 36 | 5.33 ± 0.21 | 51.5 | 46.1 | 2.4 | 35.7 | 54.8 | 9.5 | 95.5 | 4.5 |
| 12 | 20 | 5.96 ± 0.34 | 48.9 | 49.2 | 1.9 | 22.2 | 59.3 | 18.5 | 94.7 | 5.3 |
| 15 | 15 | 5.87 ± 0.33 ^a | 43.3 | 54.4 | 2.3 | 10.7 | 78.6 | 10.7 | 85.7 | 14.3 |

Note: E = estrus; D = diestrus; P = proestrus; M = metaestrus.

Difference from the parameters at the age of 6 months in the same group: * $P < 0.05$ (Student's t -test); ** $P < 0.05$ (Fischer's exact test). Difference from the corresponding age in the control group: ^a $P < 0.05$ (Student's t -test).

Table 4. Body temperature dynamics in SHR mice treated with saline or Epitalon

| Age (mo) | Number of mice | Total cycle (without phase sub-division) | Mean body temperature (°C) | | |
|----------|----------------|--|----------------------------|-----------------------------|------------------------|
| | | | Estrus | Diestrus | Metaestrus + proestrus |
| Saline | | | | | |
| 7 | 22 | 39.95 ± 0.14 | 39.80 ± 0.30 | 40.00 ± 0.20 | 39.40 ± 0.10 |
| 12 | 22 | 38.83 ± 0.18 ^a | 38.73 ± 0.30 ^b | 38.90 ± 0.24 ^a | – |
| 15 | 17 | 38.73 ± 0.17 ^a | 38.68 ± 0.30 ^b | 38.75 ± 0.20 ^a | – |
| 17 | 12 | 38.05 ± 0.24 ^a | 37.40 | 38.10 ± 0.30 ^a | – |
| 19 | 10 | 37.70 ± 0.11 ^a | 37.60 ± 0.10 ^a | 37.70 ± 0.14 ^a | – |
| Epitalon | | | | | |
| 7 | 23 | 40.68 ± 0.16 | 40.60 ± 0.20 | 40.40 ± 0.40 | 40.96 ± 0.20 |
| 12 | 20 | 38.90 ± 0.22 ^a | 39.07 ± 0.30 ^a | 38.90 ± 0.30 ^a | – |
| 15 | 15 | 39.07 ± 0.17 ^a | 38.20 ± 0.10 ^a | 39.10 ± 0.20 ^{b,c} | – |
| 17 | 12 | 38.28 ± 0.21 ^a | 38.75 ± 0.30 ^a | 38.10 ± 0.30 ^a | – |
| 19 | 10 | 37.32 ± 0.14 ^a | 37.10 | 37.40 ± 0.15 ^a | – |

Difference from the age of 7 months in the same group is significant: ^a $P < 0.01$; ^b $P < 0.05$ (Student's t -test).

Difference with the parameter at phase estrus of the same group and age: ^c $P < 0.05$ (Student's t -test).

Table 5. Survival distribution of female SHR mice treated with saline or Epitalon

| Group | No. of survivors at the age of: | | | | | | | | | | | | | | |
|----------|---------------------------------|------|------|------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| | 3 mo | 4 mo | 6 mo | 8 mo | 10 mo | 12 mo | 14 mo | 16 mo | 18 mo | 20 mo | 22 mo | 24 mo | 26 mo | 27 mo | 28 mo |
| Saline | 50 | 50 | 38 | 36 | 36 | 34 | 33 | 28 | 20 | 16 | 10 | 2 | 0 | 0 | 0 |
| Epitalon | 50 | 49 | 39 | 36 | 34 | 33 | 32 | 25 | 17 | 14 | 11 | 7 | 3 | 3 | 0 |




Figure 1. Effect of Epitalon on the survival curves of female SHR mice. Y-axis: number of mice as percentage of total.

Table 6. Parameters of life span in female SHR mice treated with saline or Epitalon

| Parameters | Saline | Epitalon |
|---|----------------|------------------|
| Number of mice | 50 | 50 |
| Mean life span, days (M \pm S.E.) | 456 \pm 29 | 455 \pm 31 |
| Median | 512 | 487 |
| Mean life span of last 10% of survivors, days | 709 \pm 10.8 | 803 \pm 15.0* |
| Maximum life span, days | 739 | 830 (+ 12.3%) |

Differences from saline is significant: * $P < 0.01$ (Student's t -test).

mice increased for the duration of Epitalon treatment by 3.1 months (+ 13.3%, $P < 0.01$; Student's t -test) (Table 6).

Spontaneous tumor development in female SHR mice

The total tumor incidence in the control female mice was 36%. Mammary carcinomas and leukemias developed most frequently, corresponding to the oncological characteristics of female SHR mice (Anisimov et al. 1989). The treatment with Epitalon failed to influence the total or malignant tumor incidence in comparison with that of the control group. However, the incidence of leukemias during the treatment with

Epitalon decreased 6-fold ($P < 0.01$; Fischer's exact test). There was no significant difference in the incidence of any other tumors between the group of mice treated with the peptide and saline (Table 7). The treatment with Epitalon significantly shifted to right the total tumor yield curve as compared with the control group (Figure 2).

Mathematical model and estimations of survival of tumor-free and tumor-bearing mice

A mathematical analysis of the survival data of the mice from the control and melatonin-treated groups has been done separately for three different contexts: (1) for all animals in each group (total cases); (2) for fatal tumor-bearing mice, and (3) for fatal tumor-free mice. We composed the groups of animals without consideration of possible effects caused by dependence between these groups. The Gompertz model shows a slowdown (by 29.04%) of the population aging rate (calculated as α in the Gompertz equation) and a corresponding increase in MRTD under the influence of Epitalon. The mortality rate in the group of fatal tumor-free mice treated with Epitalon was decreased by 32.5% as compared with the controls ($P < 0.05$, Table 8).

Table 7. Incidence, localization and type of tumors in female SHR mice treated and not treated with Epitalon

| Parameters | Saline | Epitalon |
|--|----------------------|----------------------|
| Number of mice | 50 | 50 |
| Number of tumor-bearing mice | 18 (36%) | 16 (32%) |
| Number of malignant tumor-bearing mice | 15 (30%) | 16 (32%) |
| Total number of tumors | 25 | 22 |
| Total number of malignant tumors | 18 | 20 |
| Number of tumors per tumor-bearing mice | 1.38 | 1.38 |
| Mean life span of fatal-tumor bearing mice, days | 549 ± 29 | 551 ± 21 |
| Mean life span of fatal tumor-free animals, days | 416 ± 38 | 410 ± 43 |
| <i>Localization and type of tumors:</i> | | |
| Mammary gland: adenocarcinoma | 12 (10) ^a | 17 (13) ^b |
| Nos. of metastases | 7 | 6 |
| Leukemia | 6 | 1* |
| Lung: adenoma | 1 | 0 |
| Adenocarcinoma | 0 | 2 |
| Utery: polyp | 1 | 1 |
| Ovary: cyst | 5 | 1 |

^aTwo mice had two mammary tumors each.

^bFour mice had two mammary tumors each.

Differences from saline is significant: * $P < 0.05$ (Fischer's exact test).




Figure 2. Effect of Epitalon on total tumor yield curve in female SHR mice. Y-axis: number of tumor-bearing mice as percentage of total.

Table 8. Parameters of life span in female SHR mice treated with saline or Epitalon

| Group | Total no. of cases | Fatal tumor-bearing mice | Fatal tumor-free mice |
|---|--------------------|--------------------------|-----------------------|
| <i>Number of mice</i> | | | |
| Saline | 50 | 15 | 35 |
| Epitalon | 50 | 16 | 34 |
| <i>Mean life span (days)</i> | | | |
| Saline | 456 ± 29 | 549 ± 29 | 416 ± 38 |
| Epitalon | 455 ± 31 | 551 ± 21 | 410 ± 43 |
| <i>Mean life span of the last 10% of survivors (days)</i> | | | |
| Saline | 709 ± 10 | 731 ± 8 | 692 ± 7 |
| Epitalon | 803 ± 15* | 695 ± 16 | 827 ± 2** |
| <i>Aging rate $\alpha \times 10^3$ (days⁻¹)</i> | | | |
| Saline | 4.55 (4.43; 4.86) | 9.15 (9.02; 10.4) | 2.80 (2.74; 3.20) |
| Epitalon | 3.23 (3.15; 3.46)# | 11.8 (11.3; 11.35)# | 1.89 (1.82; 2.16)# |
| <i>MRDT (days)</i> | | | |
| Saline | 152.41 | 75.71 | 247.71 |
| Epitalon | 214.69# | 58.91# | 367.1# |

Note: Mean life spans are given as mean ± standard error; 95% confidence limits are given in parentheses; MRDT = mortality rate doubling time.

Difference from controls is significant: ^a $P < 0.05$ (Fischer's exact test); * $P < 0.05$; ** $P < 0.001$ (Student's *t*-test); # $P < 0.05$ (Cox's method).

Discussion

The results of our study show that the long-term administration of Epitalon slows down demographic aging rate, increases survival and maximum life span and decreases the development of spontaneous leukemias in female SHR mice.

Treatment with Epitalon increased the food consumption in comparison to the controls between the 5th and 16th months of their life, but the body weight was similar in both the control and Epitalon-treated group. Administration of Epitalon to female CBA mice failed to influence the body weight, and increased food consumption at the age of 12 months (Anisimov et al. 2001a). No significant differences in the age-related dynamics of body temperature between both groups were observed in SHR mice. In CBA mice a slight decrease in the body temperature under the influence of Epitalon has been observed (Anisimov et al. 2001a). Thus, it could be suggested that increased food consumption induced by Epitalon was not followed by an increase in the basal metabolic rate, because both the body weight and the body temperature were not different from the controls.

The administration of Epitalon was followed by a slowing down of the age-related disturbances in

estrous function in female SHR mice. These observations are in agreement with data obtained with Epitalon in other strains of mice – CBA and FVB/N (Anisimov et al. 2001a, 2002b). It is worth nothing that long-term administration of melatonin or pineal peptide preparation Epithalamin was also followed by a slowdown of age-related switching-off of reproductive function in SHR, C3H/Sn and CBA mice and rats (Anisimov et al. 1989, 1998, 2001a, b; Meredith et al. 2000).

The aging process predisposes cells to accumulate mutations, some of which are necessary for initiation of tumor growth in target tissues (Vijg 2000; Bodyak et al. 2002). The incidence of chromosome aberrations increases with age in different strains of mice (Crowley and Curtis 1963; Sato et al. 1995). Previously we found age-related increases in chromosome aberrations in bone marrow cells and in primary spermatocytes in male SHR mice (Rosenfeld et al. 2001). In this study we observed a significant increase in the frequency of chromosome aberrations in the bone marrow cells in 12-month-old female SHR mice compared to 3-month-old specimens. Long-term treatment with Epitalon significantly decreased the age-associated increase in chromosome aberrations in female SHR mice. It was shown earlier that Epitalon

also inhibited the incidence of chromosome aberration in one-year-old senescence-accelerated mice (Rosenfeld et al. 2002).

The long-term administration of Epitalon failed to influence total spontaneous tumor incidence in female SHR mice, but it significantly inhibited the development of leukemias ($P < 0.001$) (Table 7). Treatment with Epitalon inhibited the growth of transplanted sarcoma M-1 (Khavinson et al. 2001b), decreased spontaneous tumor incidence in female CBA mice (mainly lung adenomas) (Anisimov et al. 2001a) and in *HER-2/neu* transgenic mice (Anisimov et al. 2002b). It also inhibited colon carcinogenesis induced by 1,2-dimethylhydrazine in rats (Anisimov et al. 2002a). It is possible to suggest that the capacity of Epitalon to prevent the development of spontaneous leukemias in female SHR mice can be related to its antioxidative activity. It has been shown that Epitalon inhibits free radical processes in *D. melanogaster* and CBA mice (Anisimov et al. 2001a; Khavinson and Mylnikov 2000).

Our observation of the positive effect of Epitalon on the life span of SHR mice is in agreement with observations of similar activities of Epithalamin in SHR and C3H/Sn mice and rats (Anisimov et al. 1989, 1994) and of Epitalon in female CBA mice (Anisimov et al. 2001a). The effective concentration of Epitalon was 1000–5000 times less than that of Epithalamin. In experiments with two strains of *D. melanogaster*, Epithalamin treatment was followed by an increase in their mean life span (Khavinson and Mylnikov 2000). It is noteworthy that effective concentrations of the tetrapeptide were 1000 times less than of Epithalamin and 16,000–80 × 10⁶ times less than that of melatonin (Khavinson and Mylnikov 2000). Epithalamin increased catalase activity and decreased the level of conjugated hydroperoxides in fruit flies (Mylnikov and Lyubimova 2000). The results of this investigation agree with data obtained in previous observations on the safety of long-term administration of peptide preparations isolated from the pineal gland on their geroprotective and anti-tumour effects (Anisimov et al. 1994; Khavinson et al. 2001c; Khavinson 2002). Thus, the results obtained confirm a geroprotective potential of the peptide preparation Epithalamin (Ala-Glu-Asp-Gly).

In the heart of CBA mice, the expression of 15,247 transcripts from the cDNA library was studied by the microarray technique (Anisimov et al. 2002). The analysis of the results of hybridizing the cDNA clone containing microarrays with the heart samples of the

control and Epitalon-exposed mice revealed intensified expression of 194 clones and reduced expression of 48 clones. The analysis identified the multiple genes involved in cell division (14 genes), cell signaling/communication (14), cell structure/motility (6), cell/organism defense (13), gene/protein expression (17), metabolism (11), and genes encoded by mitochondrial DNA (5). These subgroups may include gene products that can explain some of the physiological effects described above, and form a molecular basis for the geroprotective effects of these peptides.

Acknowledgements

This study was supported by grants 99-04-48023 and 02-04-07573 from the Russian Foundation for Basic Research. The authors are very grateful to James W. Vaupel for the opportunity to use the facilities of the Max Planck Institute for Demographic Research to complete this paper, and to I. I. Mikhailova and O.V. Novikova for their excellent technical assistance.

References

- Anisimov SV, Boheler KR, Khavinson VKh and Anisimov VN (2002) Study on the effect of peptides Vilon and Epitalon on gene expression in mouse heart using microarray technology. *Bull Exp Biol Med* 133: 340–347
- Anisimov VN (2001) Life span extension and cancer risk: myths and reality. *Exp Gerontol* 36: 1101–1136
- Anisimov VN, Loktionov AS, Khavinson VKh and Morozov VG (1989) Effect of low-molecular-weight factors of thymus and pineal gland on life span and spontaneous tumour development in female of different age. *Mech Ageing Dev* 49: 245–257
- Anisimov VN, Khavinson VKh and Morozov VG (1994) Twenty years of study on effects of pineal peptide preparation: Epithalamin in experimental gerontology and oncology. *Ann N Y Acad Sci* 719: 483–493
- Anisimov VN, Mylnikov SV and Khavinson VKh (1998) Pineal peptide preparation Epithalamin increases the lifespan of fruit flies, mice and rats. *Mech Ageing Dev* 103: 123–132
- Anisimov VN, Khavinson VKh, Mikhalski AI and Yashin AI (2001a) Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice. *Mech Ageing Dev* 122: 41–68
- Anisimov VN, Zavarzina NY, Zabezhinski MA, Popovich IG, Zimina OA, Shtylik AV, Arutjunyan AV, Oparina TI, Prokopenko VM, Mikhalski AI and Yashin AI (2001b) Melatonin increases both life span and tumor incidence in female CBA mice. *J Gerontol Biol Sci* 56A: B311–B323
- Anisimov VN, Khavinson VKh, Popovich IG and Zabezhinski MA (2002a) Inhibitory effect of peptide Epitalon on colon carcinogenesis induced by 1,2-dimethylhydrazine in rats. *Cancer Lett* 183: 1–8
- Anisimov VN, Khavinson VKh, Provinciali M, Alimova IN, Baturin DA, Popovich IG, Zabezhinski MA, Imynaitov EN, Mancini

- R and Franceschi C (2002b) Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. *Int J Cancer* 101: 7–10
- Anisimov VN, Alimova IN, Baturin DA, Popovich IG, Zabezhinski MA, Manton KG, Semenchenko AV and Yashin AI (2003) The effect of melatonin treatment regimen on mammary adenocarcinoma development in HER-2/neu transgenic mice. *Int J Cancer* 103: 300–305.
- Arendt J (1995) *Melatonin and the Mammalian Pineal Gland*. Chapman & Hall, London
- Armstrong SM and Redman JR (1991) Melatonin: a chronobiotic with anti-aging properties? *Med Hypotheses* 34: 300–309
- Bartsch H, Bartsch C, Simon WE, Flehmig B, Ebels I and Lippert TH (1992) Antitumor activity of the pineal gland: effect of unidentified substances *versus* the effect of melatonin. *Oncology* 49: 27–30
- Benson B (1977) Current status of pineal peptides. *Neuroendocrinology* 24: 241–248
- Bodyak ND, Nekhaeva E, Wei JY and Khrapko K (2001) Quantitation and sequencing of somatic deleted mtDNA in single cells: evidence for partially duplicated mtDNA in aged human tissues. *Human Mol Genetics* 10: 17–24
- Butler RN, Fossel M, Harman SM, Hewad CB, Olshansky SJ, Perl TT, Rothman DJ, Rothman SM, Warner HR, West MD and Wright WE (2002) Is there an antiaging medicine? *J Gerontol Biol Sci* 57A: B333–B338
- Cox DR and Oakes D (1996) *Analysis of Survival Data*. Chapman & Hall, London
- Crowley C and Curtis HJ (1963) The development of somatic mutations in mice with age. *Proc Natl Acad Sci USA* 49: 625–628
- De Grey ADNJ, Baynes JW, Berd D, Heard CH, Pawelec G and Stock G (2002) Is human aging still mysterious enough to be left only to scientists? *BioEssays* 24: 667–676
- Gart JJ, Krewski D, Lee PN, Tarone S and Wahrendorf J (1986) *Statistical Methods in Cancer Research. Vol III – The Design and Analysis of Long-Term Animal Experiments*. IARC Scientific Publication 79. IARC, Lyon
- Gauss System and Graphic Manual (1994) Aptech Systems, Inc., Maple Valley
- Goubler EV (1978) *Computing Methods of Pathology Analysis and Recognition*. Meditsina, Leningrad
- Khavinson VKh (2002) Peptides and ageing. *Neuroendocr Lett* 23 (Suppl 3): 11–144
- Khavinson VKh and Mylnikov SV (2000) Effect of epitalone on the age-specific changes in the time course of lipid peroxidation in *Drosophila melanogaster*. *Bull Exp Biol Med* 130: 1116–1119
- Khavinson VKh, Izmailov DM and Obukhova LK (2000) Effect of Epitalon on the lifespan increase in *Drosophila melanogaster*. *Mech Ageing Dev* 120: 141–149
- Khavinson VKh, Goncharova ND and Lapin BA (2001a) Synthetic tetrapeptide Epitalon restores disturbed neuroendocrine regulation in senescent monkeys. *Neuroendocrinol Lett* 22: 251–254
- Khavinson VKh, Iuzhakov VV, Kvetnoi IM and Malinin VV (2001b) Effect of epitalon on growth kinetics and functional morphology of M-1 sarcoma. *Vopr Onkol* 47: 461–466
- Khavinson VKh, Morozov VG and Anisimov VN (2001c) Experimental studies of the pineal gland preparation Epithalamin. In: Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky WJM and Mecke D (eds) *The Pineal Gland and Cancer*, pp 294–306. Springer-Verlag, Berlin/Heidelberg
- Lapin V and Ebels I (1976) Effect of some low molecular weight sheep pineal fractions and melatonin on different tumours in rats and mice. *Oncology* 33: 11–13
- Lesnikov VA and Pierpaoli W (1994) Pineal cross-transplantation (old-to-young and vice versa) as evidence for an endogenous 'aging clock'. *Ann N Y Acad Sci* 719: 461–473
- Malm OJ, Skaug OE and Lingjaerde P (1959) The effect of pinealectomy on bodily growth. *Acta Endocrinol* 30: 22–28
- Meredith S, Jackson K and Edwards P (1998) Long-term supplementation with melatonin delays reproductive senescence in female rats, without an effect on number of primordial follicles. *Exp Gerontol* 35: 343–352
- Mylnikov SV and Lyubimova NE (2000) Effect of pineal peptides on mortality rate and antioxidant capacity in *Drosophila melanogaster*. *Adv Gerontol* 4: 84–87
- Oxenkrug G, Requentina P and Bachurin S (2001) Antioxidant and antiaging activity of N-acetylserotonin and melatonin in the *in vivo* models. *Ann N Y Acad Sci* 939: 190–199
- Pierpaoli W (1998) Neuroimmunomodulation of aging. A program in the pineal gland. *Ann N Y Acad Sci* 840: 491–497
- Pierpaoli W and Regelson W (1994) Pineal control of aging: effect of melatonin and pineal grafting on aging mice. *Proc Natl Acad Sci USA* 91: 787–791
- Reiter RJ (1995) The pineal gland and melatonin in relation to aging: a summary of the theories and of the data. *Exp Gerontol* 30: 199–212
- Reiter RJ, Tan DX, Kim SJ, Manchester LC, Qi W, Garcia JJ, Cabrera JC, El-Sokkary G and Rouvier-Garay V (1999) Augmentation of indices of oxidative damage in life-long melatonin-deficient rats. *Mech Ageing Dev* 110: 157–173
- Reiter RJ, Tan DX and Allegra M (2002) Melatonin: reducing molecular pathology and dysfunction due to free radicals and associated reactant. *Neuroendocr Lett* 23 (Suppl 1): 3–8
- Reppert SM and Weaver DR (1995) Melatonin madness. *Cell* 83: 1059–1062
- Rosenfeld SV, Togo EF, Mikheev VS, Popovich IG, Zabezhinski MA and Anisimov VN (2001) Dynamics of chromosomal aberrations in male mice of various strains during aging. *Bull Exp Biol Med* 131: 482–483
- Rosenfeld SV, Togo EF, Mikheev VS, Popovich IG, Khavinson VKh and Anisimov VN (2002) Effect of epitalon on the incidence of chromosome aberrations in senescence-accelerated mice. *Bull Exp Biol Med* 133: 274–276
- Sato S, Taketomi M, Nakajima M, Kitazawa M, Shimada H, Itoh S, Igarashi M, Higashikuni N, Sutou S and Sisaki YF (1995) Effect of aging on spontaneous micronucleus frequencies in peripheral blood of in nine mouse strains. *Mutat Res* 338: 51–57
- Turusov VS and Mohr U (eds) (1994) *Pathology of Tumours in Laboratory Animals. Volume I. Tumours of the Mouse*, 2nd ed. IARC Sci Publ No 111. IARC, Lyon
- Vijg J (2000) Somatic mutations and aging: a re-evaluation. *Mutat Res* 447: 117–135
- Yuwiler A and Brammer GL (1993) Neurotransmitters and peptides in the pineal gland. In: Wettenberg L (ed) *Light and Biological Rhythms in Man*, pp 133–144. Pergamon Press, Oxford